Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma

– Presented at 23rd Annual Scientific Meeting of the Society for Neuro-Oncology – BURLINGTON, Mass.…

Blue Earth Diagnostics Announces 18F-Fluciclovine Research Presentation at Upcoming Society for Neuro-Oncology (SNO) Annual Scientific Meeting

BURLINGTON, Mass. and OXFORD, UK, November 14, 2018 – Blue Earth Diagnostics, a molecular imaging…

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming ASTRO Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, October 17, 2018 – Blue Earth Diagnostics, a molecular imaging…

Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award

Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Axumin® (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS, for use in PET imaging of suspected recurrent prostate cancer

Oxford, UK – October 2, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award

Oxford, UK – August 9, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics…

Blue Earth Diagnostics appoints IASON Sp. z o.o. to manufacture and distribute Axumin® (fluciclovine (18F)) in Poland

Supports Blue Earth Diagnostics’ goal to make Axumin commercially available across Europe Oxford, UK –…

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, June 18, 2018 – Blue Earth Diagnostics, a molecular imaging…